

Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein

Cat. No. MHC-HM408T

Description

Source	Recombinant Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and PLFQVPEPV peptide.
Accession	A0A140T913(HLA-A*02:01)&P61769(B2M)&PLFQVPEPV
Molecular Weight	The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per ug by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins. CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response.


Assay Data

Bis-Tris PAGE



Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

SEC-HPLC



The purity of Human HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer is greater than 95% as determined by SEC-HPLC.